18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

about

18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

Item

http://www.wikidata.org/entity/Q52801683

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@en

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@nl

type

Item

label

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@en

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@nl

prefLabel

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@en

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@nl

P1476

18F-FDOPA PET/MRI for monitori ...... n with recurrent brain tumors.

@en

P2093

Amy Barone

http://www.w3.org/2001/XMLSchema#string

Ephraim Parent

http://www.w3.org/2001/XMLSchema#string

Hayden Leeds

http://www.w3.org/2001/XMLSchema#string

Jonathan McConathy

http://www.w3.org/2001/XMLSchema#string

Joshua Rubin

http://www.w3.org/2001/XMLSchema#string

Karen Gauvain

http://www.w3.org/2001/XMLSchema#string

Maria Rosana Ponisio

http://www.w3.org/2001/XMLSchema#string

Michael Grimaldi

http://www.w3.org/2001/XMLSchema#string

P2860

Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients

Radiolabeled amino acids for oncologic imaging

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.

Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience.

Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.

[11C]-L-methionine positron emission tomography in the management of children and young adults with brain tumors.

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

P304

28-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NOP/NPX008

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Manu S Goyal

P577

2017-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29692922

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5909807

http://www.w3.org/2001/XMLSchema#string